Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
How much is a new treatment for pink eye worth? For one on the verge of Phase 3 testing, about $300 million.
That’s the figure Shire, the Ireland and Lexington, MA-based... Read more »
Biotech was in recovery mode this week. After Biogen’s (NASDAQ: BIIB) disappointing quarterly results send the sector’s indices downward, investors looked to other industry stalwarts, like Gilead Sciences (NASDAQ: GILD... Read more »
It looks like Synergy Pharmaceuticals may have a drug on its hands.
Shares of the New York-based company surged over 15 percent in pre-market trading this morning after its drug for... Read more »
It’ll be several years before we’ll know whether the efforts of Accelerate Long Island lead to successful, sustainable companies. But with the emergence of its latest graduate today, Envisagenics, Accelerate LI... Read more »
Regeneron Pharmaceuticals has risen to prominence in part by working with Sanofi to develop drugs for a number of diseases, most recently high cholesterol. Now the two are trying their hands... Read more »
It’s been a tumultuous few years for Aegerion Pharmaceuticals, marred by a stalled drug launch, the rise of new competitors, and a plummeting stock. And today its embattled CEO is leaving... Read more »
This week offered a reminder of how quickly success can come and go in biotech. One of the Boston area’s stalwart biotechs saw its stock land right back where it had... Read more »
The concept of “disruption” has become a buzzword in biotech, a term signifying the dreams of companies looking to make a big impact on the world of healthcare. Yet that type... Read more »
Tiny biotech RaNA Therapeutics brought in Wall Street-savvy CEO Ronald Renaud last year, and today the startup announced its biggest round of funding to date led by an investor whose past... Read more »
Despite the billions of dollars poured into Alzheimer’s disease research, the disorder remains a biological riddle with no cure. That’s why even hints of progress—encouraging signs in early studies, for example—garner... Read more »
It’s not often that a biotech with a single drug in clinical testing can bounce back from a trial that not only fails, but bombs spectacularly. But by the skin of... Read more »
We’ve got a new site launch, local IPOs, and much more to dig through in this week’s roundup. But first, a programming note to you Xconomy readers: I’ll be away on... Read more »
Catabasis Pharmaceuticals has done some strategic tinkering over the past few years, and the Cambridge, MA-based company did a bit more maneuvering on Wednesday to price its IPO.
Catabasis is set... Read more »
Back in March, Epizyme regained most of the rights to a drug it’s been developing for a wide array of cancers. There’s still a long way to go, but the move... Read more »
It’s been a jam-packed few months for Flagship Ventures, one of the Boston area’s most well-known biotech startup creators.
If microchip systems that act like organs are ever going to really change preclinical drug development, it’s going to happen one experiment—and Big Pharma adopter—at a time. Emulate is trying to... Read more »
Aerie Pharmaceuticals took a big step back earlier this year when its glaucoma drug came up short in the first of a few Phase 3 trials. But the Bedminster, NJ-based company... Read more »
In a friendly IPO market for biotechs, going public the other way—reverse merging with a shell company—is understandably the path less trodden. But after a strategic reinvention, it was the best... Read more »
New startups. New data. Financings. Acquisitions. Legal tussles. FDA advisory panels. It’s been that kind of week in East Coast biotech. So grab some coffee and let’s roll through this week’s... Read more »
© 2007-2015, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.